BFRI — Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
- Exchange: NASDAQ
- Employees: 92
- Website: https://www.biofrontera-us.com
Latest SEC filings for BFRI
- 8-K — 2026-09-14
- 10-Q — 2026-08-13
- 8-K — 2026-08-13
- 10-K/A — 2026-07-22
- 8-K — 2026-06-17
- 10-Q — 2026-05-14
- 8-K — 2026-05-14
- 10-K — 2026-03-19
- 8-K — 2026-03-19
- 8-K — 2026-03-09
Latest BFRI news
- — Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body (globenewswire.com)
- — Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast
Educational tool only — not investment advice.